Flunisolide nasal spray for the treatment of children with seasonal allergic rhinitis.
Forty-eight children with seasonal allergic rhinitis received either 150 microgram/day of flunisolide (a new topical steroid) or placebo. Those receiving flunisolide had a significantly shorter daily duration of sneezing, stuffy nose, runny nose and throat itch. Total or substantial control of their symptoms was reported by 67% of the flunisolide group and 25% of the placebo group.
D000281:Administration, Intranasal; D000293:Adolescent; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005446:Fluocinolone Acetonide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D011058:Pollen; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D012621:Seasons
D005446:Fluocinolone Acetonide; C007734:flunisolide